Back to Search
Start Over
Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
- Source :
- BMC Cardiovascular Disorders, Vol 18, Iss 1, Pp 1-8 (2018), BMC Cardiovascular Disorders
- Publication Year :
- 2018
- Publisher :
- BMC, 2018.
-
Abstract
- Background There is a little evidence for the effects of catheter ablation (CA) on hard endpoints in patients with atrial fibrillation (AF) and heart failure (HF). Methods PubMed, Embase and Cochrane Library were searched for randomized controlled trials (RCTs) enrolling patients with AF and HF who were assigned to CA, rate control or medical rhythm control groups. This meta-analysis was performed by using random-effect models. Results Seven RCTs enrolling 856 participants were included in this meta-analysis. CA reduced the risks of all-cause mortality (risk ratio [RR] 0.52, 95% CI 0.35 to 0.76), HF readmission (RR 0.58, 95% CI 0.46 to 0.66) and the composite of all-cause mortality and HF readmission (RR 0.55, 95% CI 0.47 to 0.66) when compared with control. But there was no significant difference in cerebrovascular accident (RR 0.56, 95% CI 0.23 to 1.36) between two groups. Compared with control, CA was associated with improvement in left ventricular ejection fraction (mean difference [MD] 7.57, 95% CI 3.72 to 11.41), left ventricular end systolic volume (MD -14.51, 95% CI -26.84 to − 2.07), and left ventricular end diastolic volume (MD -3.78, 95% CI -18.51 to 10.96). Patients undergoing CA exhibited increased peak oxygen consumption (MD 3.16, 95% CI 1.09 to 5.23), longer 6-min walk test distance (MD 26.67, 95% CI 12.07 to 41.27), and reduced Minnesota Living with Heart Failure Questionnaire scores (MD -9.49, 95% CI -14.64 to − 4.34) than those in control group. Compared with control, CA was associated with improved New York Heart Association class (MD -0.74, 95% CI -0.83 to − 0.64) and lower B-type natriuretic peptide levels (MD -105.96, 95% CI -230.56 to 19.64). Conclusions CA was associated with improved survival, morphologic changes, functional capacity and quality of life relative to control. CA should be considered in patients with AF and HF. Electronic supplementary material The online version of this article (10.1186/s12872-018-0904-3) contains supplementary material, which is available to authorized users.
- Subjects :
- Male
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_treatment
Rate control strategy
Catheter ablation
Heart failure
030204 cardiovascular system & hematology
law.invention
03 medical and health sciences
0302 clinical medicine
Postoperative Complications
Randomized controlled trial
law
Risk Factors
Internal medicine
medicine
Humans
030212 general & internal medicine
Randomized Controlled Trials as Topic
Ejection fraction
business.industry
Atrial fibrillation
Recovery of Function
Middle Aged
medicine.disease
Cardiac surgery
Treatment Outcome
Rhythm control strategy
lcsh:RC666-701
Relative risk
Cardiology
Quality of Life
End-diastolic volume
Female
Cardiology and Cardiovascular Medicine
business
Research Article
Subjects
Details
- Language :
- English
- ISSN :
- 14712261
- Volume :
- 18
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC Cardiovascular Disorders
- Accession number :
- edsair.doi.dedup.....f985885f119c050967eb3eda8fa6a90b
- Full Text :
- https://doi.org/10.1186/s12872-018-0904-3